The Src signaling pathway: a potential target in melanoma and other malignancies

Bibliography

• MARTIN GS: The hunting of the Src. Nat. Rev. Mol. Cell. Biol. (2001) 2(6):467-475.
   PubMed Web of Science ®Google Scholar
• ROUS PA: sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med. (1911) 13:397-411.
   PubMedGoogle Scholar
• RUBIN H: Quantitative relations between causative virus and cell in the Rous No. 1 chicken sarcoma. Virology (1955) 1:445-473.
   PubMed Web of Science ®Google Scholar
• MARTIN GS: Rous sarcoma virus: a function required for the maintenance of the transformed state. Nature (1970) 227:1021-1023.
   PubMed Web of Science ®Google Scholar
• CZERNILOFSKY AP, LEVINSON AD, VARMUS HE, BISHOP JM, TISCHER E, GOODMAN HM: Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for gene product. Nature (1980) 287(5779):198-203.
   PubMed Web of Science ®Google Scholar
• PARKER RC, VARMUS HE, BISHOP JM: Expression of v-src and chicken c-src in rat cells demonstrates qualitative differences between pp60v-src and pp60c-src. Cell (1984) 37(1):131-139.
   PubMed Web of Science ®Google Scholar
• HUNTER T, SEFTON BM: Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl. Acad. Sci. USA (1980) 77(3):1311-1315.
   PubMed Web of Science ®Google Scholar
• BROWN MT, COOPER JA: Regulation, substrates and functions of src. Biochim. Biophys. Acta. (1996) 1287(2-3):121-149.
   PubMed Web of Science ®Google Scholar
• MORI S, RONNSTRAND L, YOKOTE K et al.: Identification of two juxtamembrane autophosphorylation sites in the PDGFβ-receptor; involvement in the interaction with Src family tyrosine kinases. EMBO J. (1993) 12(6):2257-2264.
   PubMed Web of Science ®Google Scholar
• RAMEH LE, CHEN CS, CANTLEY LC: Phosphatidylinositol (3,4,5)P3 interacts with SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins. Cell (1995) 83(5):821-830.
   PubMed Web of Science ®Google Scholar
• MACAULEY A, COOPER JA: Structural differences between repressed and derepressed forms of p60c-src. Mol. Cell. Biol. (1989) 9(6):2648-2656.
   PubMed Web of Science ®Google Scholar
• FRAME MC: Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta. (2002) 1602(2):114-130.
   PubMed Web of Science ®Google Scholar
• PLAYFORD MP, SCHALLER MD: The interplay between Src and integrins in normal and tumor biology. Oncogene (2004) 23(48):7928-7946.
   PubMed Web of Science ®Google Scholar
• HSIA DA, MITRA SK, HAUCK CR et al.: Differential regulation of cell motility and invasion by FAK. J. Cell Biol. (2003) 160:753-767.
   PubMed Web of Science ®Google Scholar
• AVIZIENYTE E, FRAME MC: Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr. Opin. Cell Biol. (2005) 17(5):542-547.
   PubMed Web of Science ®Google Scholar
• KORNBERG LJ: Focal adhesion kinase and its potential involvement in tumor invasion and metastasis. Head Neck (1998) 20(8):745-752.
   PubMed Web of Science ®Google Scholar
• MITRA SK, MIKOLON D, MOLINA JE et al.: Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene (2006) 25(44):5969-5984.
   PubMedGoogle Scholar
• NORITAKE H, MIYAMORI H, GOTO C et al.: Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src. Clin. Exp. Metastasis (1999) 17(2):105-110.
   Google Scholar
• FUJITA Y, KRAUSE G, SCHEFFNER M et al.: Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat. Cell Biol. (2002) 4(3):222-231.
   PubMed Web of Science ®Google Scholar
• FRIXEN UH, BEHRENS J, SACHS M et al.: E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell Biol. (1991) 113(1):173-185.
   PubMed Web of Science ®Google Scholar
• YEATMAN TJ: A renaissance for SRC. Nat. Rev. Cancer (2004) 4(6):470-480.
   PubMed Web of Science ®Google Scholar
• RALSTON R, BISHOP JM: The product of the protooncogene c-src is modified during the cellular response to platelet-derived growth factor. Proc. Natl. Acad. Sci. USA (1985) 82(23):7845-7849.
   PubMed Web of Science ®Google Scholar
• TWAMLEY-STEIN GM, PEPPERKOK R, ANSORGE W, COURTNEIDGE SA: The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells. Proc. Natl. Acad. Sci. USA (1993) 90(16):7696-700.
   PubMed Web of Science ®Google Scholar
• SHAH K, VINCENT F: Divergent roles of c-Src in controlling platelet-derived growth factor-dependent signaling in fibroblasts. Mol. Biol. Cell (2005) 16(11):5418-5432.
   PubMed Web of Science ®Google Scholar
• COURTNEIDGE SA, DHAND R, PILAT D, TWAMLEY GM, WATERFIELD MD, ROUSSEL MF: Activation of Src family kinases by colony stimulating factor-1, and their association with its receptor. EMBO J. (1993) 12(3):943-950.
   PubMed Web of Science ®Google Scholar
• FLOSSMANN-KAST BB, JEHLE PM, HOEFLICH A et al.: Src stimulates insulin-like growth factor I (IGF-I)-dependent cell proliferation by increasing IGF-I receptor number in human pancreatic carcinoma cells. Cancer Res. (1998) 58(16):3551-3554.
   PubMed Web of Science ®Google Scholar
• RAHIMI N, HUNG W, TREMBLAY E, SAULNIER R, ELLIOTT B: c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J. Biol. Chem. (1998) 273(50):33714-21.
   PubMed Web of Science ®Google Scholar
• TICE DA, BISCARDI JS, NICKLES AL, PARSONS SJ: Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA (1999) 96(4):1415-1420.
   PubMed Web of Science ®Google Scholar
• YU CL, MEYER DJ, CAMPBELL GS et al.: Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science (1995) 269(5220):81-83.
   PubMed Web of Science ®Google Scholar
• BROMBERG J, DARNELL JE Jr.: The role of STATs in transcriptional control and their impact on cellular function. Oncogene (2000) 19(21):2468-2473.
   PubMed Web of Science ®Google Scholar
• LU Y, YU Q, LIU JH et al.: Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J. Biol. Chem. (2003) 278(41):40057-40066.
   PubMed Web of Science ®Google Scholar
• TAN BL, HONG L, MUNUGALAVADLA V, KAPUR R: Functional and biochemical consequences of abrogating the activation of multiple diverse early signaling pathways in Kit. Role for Src kinase pathway in Kit-induced cooperation with erythropoietin receptor. J. Biol. Chem. (2003) 278(13):11686-11695.
   PubMedGoogle Scholar
• VERBEEK BS, VROOM TM, ADRIAANSEN-SLOT SS et al.: c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J. Pathol. (1996) 180(4):383-388.
   PubMed Web of Science ®Google Scholar
• GUY CT, MUTHUSWAMY SK, CARDIFF RD, SORIANO P, MULLER WJ: Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev. (1994) 8(1):23-32.
   PubMed Web of Science ®Google Scholar
• MYOUI A, NISHIMURA R, WILLIAMS PJ et al.: c-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res. (2003) 63(16):5028-5033.
   PubMed Web of Science ®Google Scholar
• RIGGINS RB, THOMAS KS, TA HQ et al.: Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res. (2006) 66(14):7007-7015.
   PubMed Web of Science ®Google Scholar
• RUCCI N, RECCHIA I, ANGELUCCI A et al.: Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J. Pharmacol. Exp. Ther. (2006) 318(1):161-172.
   PubMed Web of Science ®Google Scholar
• PARK HB, GOLUBOVSKAYA V, XU L et al.: Activated Src increases adhesion, survival and α2-integrin expression in human breast cancer cells. Biochem. J. (2004) 378(Pt 2):559-567.
   PubMed Web of Science ®Google Scholar
• TAN M, LI P, KLOS KS et al.: ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Res. (2005) 65(5):1858-1867.
   PubMed Web of Science ®Google Scholar
• CARTWRIGHT CA, KAMPS MP, MEISLER AI et al.: pp60c-src activation in human colon carcinoma. J. Clin. Invest. (1989) 83(6):2025-2033.
   PubMed Web of Science ®Google Scholar
• CARTWRIGHT CA, MEISLER AI, ECKHART W: Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc. Natl. Acad. Sci. USA (1990) 87(2):558-562.
   PubMed Web of Science ®Google Scholar
• BOLEN JB, VEILLETTE A, SCHWARTZ AM, DESEAU V, ROSEN N: Analysis of pp60c-src in human colon carcinoma and normal human colon mucosal cells. Oncogene Res. (1987) 1(2):149-168.
   PubMedGoogle Scholar
• BOLEN JB, VEILLETTE A, SCHWARTZ AM , DESEAU V, ROSEN N et al.: Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc. Natl. Acad. Sci. USA (1987) 84(8):2251-2255.
   PubMed Web of Science ®Google Scholar
• TALAMONTI MS, ROH MS, CURLEY SA, GALLICK GE: Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J. Clin. Invest. (1993) 91(1):53-60.
   PubMed Web of Science ®Google Scholar
• TERMUHLEN PM, CURLEY SA, TALAMONTI MS, SABOORIAN MH, GALLICK GE: Site-specific differences in pp60c-src activity in human colorectal metastases. J. Surg. Res. (1993) 54(4):293-298.
   PubMed Web of Science ®Google Scholar
• IRBY RB, YEATMAN TJ: Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Res. (2002) 62(9):2669-2674.
   PubMed Web of Science ®Google Scholar
• IRBY RB, MAO W, COPPOLA D et al.: Activating SRC mutation in a subset of advanced human colon cancers. Nat. Genet. (1999) 21(2):187-190.
   PubMed Web of Science ®Google Scholar
• DAIGO Y, FURUKAWA Y, KAWASOE T et al.: Absence of genetic alteration at codon 531 of the human c-src gene in 479 advanced colorectal cancers from Japanese and Caucasian patients. Cancer Res. (1999) 59(17):4222-4224.
   PubMed Web of Science ®Google Scholar
• XI S, ZHANG Q, DYER KF et al.: Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J. Biol. Chem. (2003) 278(34):31574-31583.
   PubMed Web of Science ®Google Scholar
• ZHANG Q, THOMAS SM, XI S et al.: SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res. (2004) 64(17):6166-6173.
   PubMed Web of Science ®Google Scholar
• LUTZ MP, ESSER IB, FLOSSMANN-KAST BB et al.: Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. Commun. (1998) 243(2):503-508.
   PubMed Web of Science ®Google Scholar
• VISSER CJ, RIJKSEN G, WOUTERSEN RA, DE WEGER RA: Increased immunoreactivity and protein tyrosine kinase activity of the protooncogene pp60c-src in preneoplastic lesions in rat pancreas. Lab. Invest. (1996) 74(1):2-11.
   Google Scholar
• TREVINO JG, SUMMY JM, LESSLIE DP et al.: Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am. J. Pathol. (2006) 168(3):962-972.
   PubMed Web of Science ®Google Scholar
• DUXBURY MS, ITO H, ZINNER MJ, ASHLEY SW, WHANG EE: Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin. Cancer Res. (2004) 10(7):2307-2318.
   PubMed Web of Science ®Google Scholar
• MAZURENKO NN, KOGAN EA, ZBOROVSKAYA IB, KISSELJOV FL: Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur. J. Cancer. (1992) 28(2-3):372-377.
   PubMed Web of Science ®Google Scholar
• JOHNSON FM, SAIGAL B, TALPAZ M, DONATO NJ: Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin. Cancer Res. (2005) 11(19 Pt 1):6924-6932.
   PubMed Web of Science ®Google Scholar
• SONG L, MORRIS M, BAGUI T, LEE FY, JOVE R, HAURA EB: Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. (2006) 66(11):5542-5548.
   PubMed Web of Science ®Google Scholar
• KUMBLE S, OMARY MB, CARTWRIGHT CA, TRIADAFILOPOULOS G: Src activation in malignant and premalignant epithelia of Barrett’s esophagus. Gastroenterology (1997) 112(2):348-356.
   Google Scholar
• IRAVANI S, ZHANG HQ, YUAN ZQ et al.: Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett’s neoplasia. Hum. Pathol. (2003) 34(10):975-982.
   PubMed Web of Science ®Google Scholar
• WANG X, WANG C, WANG W, HUANG G: [Relationship between the express product of src gene (pp60c-src) and the initiation of gastric carcinoma]. Hua Xi Yi Ke Da Xue Xue Bao (1996) 27(1):71-74.
   Google Scholar
• STETTNER MR, WANG W, NABORS LB et al.: Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res. (2005) 65(13):5535-5543.
   PubMed Web of Science ®Google Scholar
• AMOS S, MARTIN PM, POLAR GA, PARSONS SJ, HUSSAINI IM: Phorbol 12-myriState 13-acetate induces epidermal growth factor receptor transactivation via protein kinase Cδ/c-Src pathways in glioblastoma cells. J. Biol. Chem. (2005) 280(9):7729-7738.
   PubMedGoogle Scholar
• ANGERS-LOUSTAU A, HERING R, WERBOWETSKI TE, KAPLAN DR, DEL MAESTRO RF: SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol. Cancer Res. (2004) 2(11):595-605.
   Google Scholar
• LUND CV, NGUYEN MT, OWENS GC et al.: Reduced glioma infiltration in Src-deficient mice. J. Neurooncol. (2006) 78(1):19-29.
   PubMed Web of Science ®Google Scholar
• KITANAKA A, WAKI M, KAMANO H et al.: Antisense src expression inhibits proliferation and erythropoietin-induced erythroid differentiation of K562 human leukemia cells. Biochem. Biophys. Res. Commun. (1994) 201:1534-1540.
   Google Scholar
• MERMEL CH, MCLEMORE ML, LIU F et al.: Src-family kinases are important negative regulators of G-CSF dependent granulopoiesis. Blood (2006) 108(8):2562-2568.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Src transduces signaling via growth hormone (GH)-activated GH receptor (GHR) tyrosine-phosphorylating GHR and STAT5 in human leukemia cells. Leuk. Res. (2006) Epub ahead of print.
   Google Scholar
• AZAM M, NARDI V, SHAKESPEARE WC et al.: Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc. Natl. Acad. Sci. USA (2006) 103(24):9244-9249.
   PubMed Web of Science ®Google Scholar
• YONEZAWA Y, NAGASHIMA Y, SATO H et al.: Contribution of the Src family of kinases to the appearance of malignant phenotypes in renal cancer cells. Mol. Carcinog. (2005) 43(4):188-197.
   PubMed Web of Science ®Google Scholar
• FUJIMOTO E, SATO H, NAGASHIMA Y et al.: A Src family inhibitor (PP1) potentiates tumor-suppressive effect of connexin 32 gene in renal cancer cells. Life Sci. (2005) 76(23):2711-2720.
   Google Scholar
• FANNING P, BULOVAS K, SAINI KS et al.: Elevated expression of pp60c-src in low grade human bladder carcinoma. Cancer Res. (1992) 52(6):1457-1462.
   PubMed Web of Science ®Google Scholar
• CHIANG GJ, BILLMEYER BR, CANES D et al.: The src-family kinase inhibitor PP2 suppresses the in vitro invasive phenotype of bladder carcinoma cells via modulation of Akt. BJU Int. (2005) 96(3):416-422.
   Google Scholar
• WIENER JR, WINDHAM TC, ESTRELLA VC et al.: Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol. Oncol. (2003) 88(1):73-79.
   PubMed Web of Science ®Google Scholar
• WIENER JR, NAKANO K, KRUZELOCK RP, BUCANA CD, BAST RC Jr, GALLICK GE: Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin. Cancer Res. (1999) 5(8):2164-2170.
   PubMed Web of Science ®Google Scholar
• MIOTTI S, TOMASSETTI A, FACETTI I, SANNA E, BERNO V, CANEVARI S: Simultaneous expression of caveolin-1 and E-cadherin in ovarian carcinoma cells stabilizes adherens junctions through inhibition of src-related kinases. Am. J. Pathol. (2005) 167(5):1411-1427.
   PubMedGoogle Scholar
• GEORGE JA, CHEN T, TAYLOR CC: SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res. (2005) 65(22):10381-10388.
   PubMed Web of Science ®Google Scholar
• CHEN T, PENGETNZE Y, TAYLOR CC: Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol. Cancer Ther. (2005) 4(2):217-224.
   PubMed Web of Science ®Google Scholar
• PARONETTO MP, FARINI D, SAMMARCO I et al.: Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer. Am. J. Pathol. (2004) 164(4):1243-1251.
   PubMed Web of Science ®Google Scholar
• LEE LF, LOUIE MC, DESAI SJ et al.: Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene (2004) 23(12):2197-205.
   PubMed Web of Science ®Google Scholar
• NAM S, KIM D, CHENG JQ et al.: Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. (2005) 65(20):9185-9189.
   PubMed Web of Science ®Google Scholar
• SLACK JK, ADAMS RB, ROVIN JD, BISSONETTE EA, STOKER CE, PARSONS JT: Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene (2001) 20(10):1152-1163.
   PubMed Web of Science ®Google Scholar
• MUNSHI N, GROOPMAN JE, GILL PS, GANJU RK: c-Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi’s sarcoma cells. J. Immunol. (2000) 164(3):1169-1174.
   PubMedGoogle Scholar
• DIAZ-MONTERO CM, WYGANT JN, MCINTYRE BW: PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation. Eur. J. Cancer. (2006) 42(10):1491-500.
   PubMed Web of Science ®Google Scholar
• BUDDE RJ, KE S, LEVIN VA: Activity of pp60c-src in 60 different cell lines derived from human tumors. Cancer Biochem. Biophys. (1994) 14(3):171-175.
   PubMedGoogle Scholar
• MIRMOHAMMADSADEGH A, HASSAN M, BARDENHEUER W et al.: STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J. Invest. Dermatol. (2006) Epub ahead of print.
   Google Scholar
• NIU G, BOWMAN T, HUANG M et al.: Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene (2002) 21(46):7001-7010.
   PubMed Web of Science ®Google Scholar
• DECONTI RM, MESSINA JM, DECKER M et al.: Expression of STAT proteins and interferon-α receptors in benign and malignant melanocytic lesions: correlation with recurrence. 2004 ASCO Annual Meeting Proceedings (2004).
   Google Scholar
• NIU G, SHAIN KH, HUANG M et al.: Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res. (2001) 61(8):3276-3280.
   PubMed Web of Science ®Google Scholar
• NIU G, HELLER R, CATLETT-FALCONE R et al.: Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. (1999) 59(20):5059-5063.
   PubMed Web of Science ®Google Scholar
• BECKER D, LEE PL, RODECK U, HERLYN M: Inhibition of the fibroblast growth factor receptor 1(FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. Oncogene (1992) 7(11):2303-2313.
   PubMed Web of Science ®Google Scholar
• YAYON A, MA YS, SAFRAN M, KLAGSBRUN M, HALABAN R: Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: evidence for the involvement of Src-family kinases. Oncogene (1997) 14(25):2999-3009.
   Google Scholar
• QI J, CHEN N, WANG J, SIU CH: Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the β-catenin signaling pathway. Mol. Biol. Cell. (2005) 16(9):4386-4397.
   PubMed Web of Science ®Google Scholar
• QI J, WANG J, ROMANYUK O, SIU CH: Involvement of Src family kinases in N-cadherin phosphorylation and β-catenin dissociation during transendothelial migration of melanoma cells. Mol. Biol. Cell. (2006) 17(3):1261-1272.
   PubMed Web of Science ®Google Scholar
• HOMSI J, MESSINA J, CUBITT C et al.: Targeting Src/Stat3 pathway in malignant melanoma. 2006 ASCO Annual Meeting Proceedings Part I (2006) 24(18S Suppl.):8025.
   Google Scholar
• SCHITTENHELM MM, SHIRAGA S, SCHROEDER A et al.: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. (2006) 66(1):473-481.
   PubMed Web of Science ®Google Scholar
• CHEN Z, LEE FY, BHALLA KN, WU J: Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol. Pharmacol. (2006) 69(5):1527-1533.
   PubMed Web of Science ®Google Scholar
• TALPAZ M, SHAH NP, KANTARJIAN H et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. (2006) 354(24):2531-2541.
   PubMed Web of Science ®Google Scholar
• HOCHHAUS A, KANTARJIAN H, BACCARANI M et al.: Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: results of the CA180013 ‘START-C’ Study. 2006 ASCO Annual Meeting Proceedings. Abstract 6508.
   Google Scholar
• GOLAS JM, ARNDT K, ETIENNE C et al.: SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. (2003) 63:375-381.
   PubMed Web of Science ®Google Scholar
• DORSEY JF, JOVE R, KRAKER AJ, WU J: The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res. (2000) 60(12):3127-3131.
   PubMed Web of Science ®Google Scholar
• HUANG M, DORSEY JF, EPLING-BURNETTE PK et al.: Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene (2002) 21(57):8804-8816.
   PubMed Web of Science ®Google Scholar